General
Preferred name
eltrombopag
Synonyms
SB-497115-GR ()
SB-497115 ()
Promacta Olamine ()
Revolade ()
Eltrombopag diethanolamine salt ()
SB497115 ()
SB-497115GR ()
ELTROMBOPAG OLAMINE ()
Eltrombopag (Olamine) ()
Eltrombopag (SB497115) Olamine ()
SB-497115-GR, Revolade, Promacta,Promacta Olamine ()
Eltrombopag (as olamine) ()
Promacta kit ()
Promacta ()
Eltrombopag compd with 2-aminoethanol (1:2) ()
Alvaiz ()
ELTROMBOPAG CHOLINE ()
Eltrombopag-13C4 ()
P&D ID
PD009319
CAS
496775-61-2
496775-62-3
Tags
available
drug
Approved by
EMA
FDA
First approval
2023
2008
Drug Status
approved
investigational
Max Phase
4.0
Drug indication
autoimmune thrombocytopenic purpura
hemorrhage
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well[1][2][3][4][5].
PRICE 96
DESCRIPTION Eltrombopag is a thrombopoietin receptor agonist that increases production of platelets. The structure shown here represents the compound with double bond stereochemistry as stipulated in the INN record for this drug. Representations on other chemistry databases may show alternative tautomers. The marketed drug contains eltrombopag olamine (PubChem CID 71719015, again note tautomer difference). (GtoPdb)
HALF-LIFE About 21-32 hours in healthy patients.; About 26-35 hours in patients with idiopathic thrombocytopenic purpura.
DESCRIPTION Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well[1][2][3][4][5].
PRICE 62
DESCRIPTION Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active small-molecule, nonpeptide thrombopoietin receptor agonist that stimulates megakaryopoiesis. It binds to and activates the transmembrane domain of the platelet thrombopoietin receptor (TPO-R or CD110), promoting the proliferation and differentiation of megakaryocytic cells and enhancing platelet production. (TargetMol Bioactive Compound Library)
DESCRIPTION Eltrombopag (SB-497115-GR), an orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity, binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110). (TargetMol Bioactive Compound Library)
Cell lines
1
Organisms
1
Compound Sets
25
Axon Medchem Screening Library
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
External IDs
198
Properties
(calculated by RDKit )
Molecular Weight
442.16
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
4
Aromatic Ring Count
3
cLogP
4.56
TPSA
114.59
Fraction CSP3
0.12
Chiral centers
0.0
Largest ring
6.0
QED
0.4
Structural alerts
1
imine_one_fives(89)
[#6]-1=[!#1]-[!#6&!#1]-[#6](-[#6]-1=[!#6&!#1;!R])=[#8]
PAINS Family B
Custom attributes
(extracted from source data)
MOA
thrombopoietin receptor agonist
Thrombin agonist
Target
Thrombopoietin Receptor
MPL
TpoR agonist
TpoR
Bacterial
Disease Area
hematology, infectious disease
Indication
anemia, hepatitis C, thrombocytopenia
Pathway
Anti-infection
Apoptosis
Immunology/Inflammation
Proteases/Proteasome
Source data